Volume 7.24 | Jun 25

Mammary Cell News 7.24 June 25, 2015
Mammary Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook   MCN on Twitter
Stress Hormones Could Undermine Breast Cancer Therapy
Researchers have discovered that the hormone progesterone, an ingredient in contraceptives and menopausal hormone replacement therapies, might stimulate the growth of breast cancer cells that are resistant to anti-estrogen therapy and chemotherapy. [Press release from Thomas Jefferson University discussing online prepublication in Oncogene] Press Release | Full Article
Dissociation Enzymes For Optimized Human Mammary Tissue Dissociation and Culture FREE Protocols
PUBLICATIONS (Ranked by impact factor of the journal)

Haploinsufficiency for BRCA1 Leads to Cell-Type-Specific Genomic Instability and Premature Senescence
Researchers showed that human mammary epithelial cells from BRCA1-mutation carriers exhibit increased genomic instability and rapid telomere erosion in the absence of tumor-suppressor loss. They further uncovered a novel form of haploinsufficiency-induced senescence specific to epithelial cells, which is triggered by pRb pathway activation rather than p53 induction. [Nat Commun] Full Article

Shrapnel Nanoparticles Loading Docetaxel Inhibit Metastasis and Growth of Breast Cancer
To inhibit the metastasis and growth of breast cancer simultaneously, a new docetaxel loaded shrapnel nano delivery system with the reduction- and enzyme-sensitive properties was designed and developed. [Biomaterials] Abstract

LGR5 Promotes Breast Cancer Progression and Maintains Stem-Like Cells through Activation of Wnt/β-Catenin Signaling
To determine the mechanism of cancer stem cells (CSCs) in breast cancer, scientists focused on LGR5, a marker of adult stem cells that potentially serves as a functional factor in CSCs. LGR5 promoted cell mobility, tumor formation and EMT in breast cancer cells by activating Wnt/β-catenin signaling. [Stem Cells] Abstract

Synthesis, Characterization and Apoptotic Activity of Quinazolinone Schiff Base Derivatives toward MCF-7 Cells via Intrinsic and Extrinsic Apoptosis Pathways
The authors investigated the cytotoxic effect of 3-(5-chloro-2-hydroxybenzylideneamino)-2-(5-chloro-2-hydroxyphenyl)-2,3-dihydroquinazolin-4(1H)-one and 3-(5-nitro-2-hydroxybenzylideneamino)-2-(5-nitro-2-hydroxyphenyl)-2,3-dihydroquinazolin-4(1H)-one on MCF-7, MDA-MB-231, MCF-10A and WRL-68 cells. [Sci Rep] Full Article

IGF1R/IRS1 Signaling Confers Pathogenic Activity on Breast Tumor Cells Lacking REST
Analysis of breast tumor cell lines showed RE-1 Silencing Transcription Factor (REST) directly represses insulin receptor substrate-1 (IRS1), and cells lacking REST have increased levels of IRS1 mRNA and protein. Scientists found upregulation of IRS1 function is both necessary and sufficient for enhanced signaling and growth in breast cancer cells lacking REST. [Mol Cell Biol] Abstract

MiR-133a Is Functionally Involved in Doxorubicin-Resistance in Breast Cancer Cells MCF-7 via Its Regulation of the Expression of Uncoupling Protein 2
Researchers showed that miR133a might play a functional role in the development of Doxorubicin-resistant in breast cancer cells. They found that lower level of miR133a is accompanied by increased expression of uncoupling protein 2 in Doxorubicin-resistant breast cancer cell line MCF-7/Dox as compared with its parental cell line MCF-7. [PLoS One] Full Article

Dual Fatty Acid Synthase and HER2 Signaling Blockade Shows Marked Antitumor Activity against Breast Cancer Models Resistant to Anti-HER2 Drugs
Investigators developed and molecularly characterized in vitro HER2+ models of resistance to trastuzumab, lapatinib and both. The cellular interactions of combining anti-fatty acid synthase polyphenolic compounds with anti-HER2 signaling drugs (trastuzumab plus pertuzumab and temsirolimus) were analyzed. [PLoS One] Full Article

The Phytoestrogen Genistein Affects Breast Cancer Cells Treatment Depending on the ERα/ERβ Ratio
Scientists investigated the effects of genistein in breast cancer cells with different ERα/ERβ ratio: MCF-7 (high ratio), T47D (low ratio) and MCF-7 overexpressing ERβ treated with cisplatin, paclitaxel or tamoxifen. Cell viability, ROS production, autophagy, apoptosis, antioxidant enzymes protein levels and cell cycle were analyzed. [J Cell Biochem] Abstract

Fisetin Regulates TPA-Induced Breast Cancer Cell Invasion by Suppressing Matrix Metalloproteinase-9 Activation via the PKC/ROS/MAPK Pathways
Investigator sdetermined the anti-invasive activity of fisetin in human breast cancer cells. Fisetin significantly attenuated 12-O-tetradecanoylphorbol-13-acetate-induced cell invasion in MCF-7 human breast cancer cells, and was found to inhibit the activation of the PKCα/ROS/ERK1/2 and p38 MAPK signaling pathways. [Eur J Pharmacol] Abstract | Graphical Abstract


Combination of Everolimus with Trastuzumab plus Paclitaxel as First-Line Treatment for Patients with HER2-Positive Advanced Breast Cancer (BOLERO-1): A Phase III, Randomized, Double-Blind, Multicenter Trial
Researchers assessed the efficacy and safety of adding everolimus to trastuzumab and paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer. [Lancet Oncol] Abstract

Capecitabine Combined with Docetaxel versus Vinorelbine Followed by Capecitabine Maintenance Medication for First-Line Treatment of Patients with Advanced Breast Cancer: Phase III Randomized Trial
Progression-free survival and the safety profiles of docetaxel/capecitabine and vinorelbine/capecitabine followed by capecitabine maintenance therapy were compared in patients with metastatic breast cancer. [Cancer] Abstract

Protocol and Data: Serum-Free, 3D Suspension Assay for Breast Cancer Cells
Palbociclib for the Treatment of Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
The authors review the development of palbociclib and its use in treatment of hormone receptor-positive metastatic breast cancer in the context of other FDA-approved agents in this setting. [Clin Cancer Res] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.
TapImmune Reports Robust Immune Responses Generated in 19 of 20 Evaluable HER2/neu Breast Cancer Patients
TapImmune Inc. reported the completion of data analysis from patients treated in a Phase I clinical trial. In this Phase I trial conducted at the Mayo Clinic in Rochester, women diagnosed with HER2+ breast cancer that had completed standard treatment at least 90 days prior to enrollment were declared disease free and were treated with a multi-peptide HER2/neu vaccine. [TapImmune Inc. (PR Newswire Association LLC)] Press Release

Peregrine Pharmaceuticals Granted Key European Patent for Its Lead Clinical Drug Candidate Bavituximab
Peregrine Pharmaceuticals, Inc. announced that the European Patent Office has granted patent number 2,269,656, titled “Selected Antibodies Binding to Aminophospholipids and their Use in Treatment, Such as Cancer”. This important patent covers bavituximab as a composition of matter and for use in treating cancer including in combination with radiotherapy or chemotherapy, such as with docetaxel. [Peregrine Pharmaceuticals, Inc.] Press Release

Merrimack Pharmaceuticals Announces Expansion of MM-398 (nal-IRI) Imaging Study to Patients with Metastatic Breast Cancer
Merrimack Pharmaceuticals, Inc. announced the initiation of clinical imaging assessing the use of a potential marker for delivery of MM-398 (irinotecan liposome injection), also known as “nal-IRI,” to metastatic breast cancer. [Merrimack Pharmaceuticals, Inc.] Press Release

Autophagy Defect Explored in Hereditary Breast Cancer
Rutgers Cancer Institute of New Jersey researchers Bing Xia, PhD, and Eileen P. White, PhD, have been awarded a $2.4 million R01 grant from the National Cancer Institute to explore the relationship between the cellular-survival mechanism of autophagy and tumor suppression function in hereditary breast cancers. [Rutgers Cancer Institute of New Jersey] Press Release

From our sponsor:
Discover how to reduce variability in primary neuron cultures with NeuroCult™ SM.
Watch the webinar.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW 3rd Annual International Conference on Advances in Medical Research (CAMR 2015)
August 17-18, 2015
Singapore, Singapore

Visit our events page to see a complete list of events in the mammary cell community.
NEW Postdoctoral Researcher – Breast Cancer (University of Oxford)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Postdoctoral Fellow – Oncolytic Viruses (Mayo Clinic – Rochester)

Postdoctoral Positions – Breast Cancer (University of Texas MD Anderson Cancer Center)

Assistant/Associate/Full Professor – Oncology (Shanghai Jiao Tong University School of Medicine)

Postdoctoral Research Assistant – Role of BRCA1 in the Repair of DNA Damage (University of Dundee)

Postdoctoral Position – Malignant Breast Cancer Cells in the Bone Marrow Microenvironment (Duke University)

Postdoctoral Position – Fatty Acid Metabolism Inhibition on Chemoresistant TNBC Models (University of Girona)

Postdoctoral Fellow – Regulation of Growth and Survival of Breast Cancer Cells (Icahn School of Medicine at Mount Sinai)

Postdoctoral Technician – Prostate/Breast Cancer (Baylor College of Medicine)

Postdoctoral Research Fellow/Instructor – Prostate/Breast Cancer (Baylor College of Medicine)

Postdoctoral Positions – Molecular Cancer Biology (University of Pennsylvania)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Mammary Cell News: Archives | Events | Contact Us